Payment overview · 2025
General Payments
$2,380.42
115 reported records · 25 companies
Healthcare provider profile · identity verified
Miranda High
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EDMOND, OK · NPI 1215529078
Verified facts
What the public records show
CMS Open Payments records show Miranda High received $2,380.42 in general payments during 2025 across 115 reported records.
Madrigal Pharmaceuticals accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $376.64 | 15.8% | 13 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $267.46 | 11.2% | 17 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $240.22 | 10.1% | 10 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $202.79 | 8.5% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $185.72 | 7.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $168.74 | 7.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.75 | 7.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.93 | 3.7% | 5 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $79.17 | 3.3% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.18 | 2.9% | 3 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $65.92 | 2.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.33 | 2.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $48.47 | 2.0% | 2 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $47.99 | 2.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.79 | 1.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.43 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.49 | 1.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.52 | 1.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.99 | 1.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.00 | 1.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.81 | 1.0% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.86 | 0.9% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $20.75 | 0.9% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.83 | 0.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.64 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,337.92 | 114 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $376.64 | 13 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $240.22 | 10 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $202.79 | 10 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $189.54 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $185.72 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $168.74 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.75 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.93 | 5 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $79.17 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $79.17 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $79.17 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $77.92 | 5 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $69.18 | 3 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $65.92 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $48.47 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $47.99 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 363 | 116 |
| Tramadol Hcl | Tramadol Hcl | 232 | 72 |
| Pregabalin | Pregabalin | 162 | 51 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 122 | 36 |
| Baclofen | Baclofen | 115 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 30 |
| Buprenorphine | Buprenorphine | 97 | 37 |
| Buprenorphine Hcl | Buprenorphine Hcl | 89 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 29 |
| Belbuca | Buprenorphine Hcl | 53 | 19 |
| Celecoxib | Celecoxib | 53 | 16 |
| Trazodone Hcl | Trazodone Hcl | 51 | suppressed |
| Methocarbamol | Methocarbamol | 49 | 25 |
| Tramadol Hcl Er | Tramadol Hcl | 45 | 15 |
| Topiramate | Topiramate | 43 | suppressed |
| Lidocaine | Lidocaine | 30 | 11 |
| Movantik | Naloxegol Oxalate | 28 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Linzess | Linaclotide | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | 11 |
| Meloxicam | Meloxicam | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,380.42 · 115 records | Madrigal Pharmaceuticals | AFREZZA, AREXVY, CeQur Simplicity, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IMCIVREE, INCEPTIV, ISTURISA, Kerendia, Korlym, NEXLETOL, NP Thyroid 60, Ozempic, RECORLEV, REZDIFFRA, Rybelsus, SHINGRIX, STRENSIQ, SYNCHROMEDII, TEPEZZA, TZIELD, UBRELVY, UNITHROID, Veozah, WaveWriter Alpha Prime 16, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error